Bristol-Myers Squibb Company (BMY) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High margins ⢠Robust FCF ⢠Very high leverage BristolâMyers Squibb shows strong margins and free cash flow that fund dividends and deleveraging, but very high debt and quarterly cash volatility materially raise solvency risk. â
Price Behavior
Key Price Behavior Insights: ⢠Defined range ⢠Close below SMA ⢠Failed breakouts Support Level: $59.50 Resistance Level: $62.30â$62.40 Over the last month BMY has traded in a clear $59.50â$62.40 range with a modest earlyâFebruary advance, but the close below the last-month SMA on 2026-03-06 and repeated failures at $62.40 weaken near-term momentum and raise the risk of a retest of $59.50.
Sentiment & News
Key News Insights: ⢠New drug growth ⢠Legacy erosion ⢠Mixed investor activity Bristol Myers Squibb beat Q4 expectations, lifting the stock as strong growth from oncology/hematology drugs (Breyanzi, Reblozyl) increasingly offsets legacy generic erosion amid mixed institutional flows and volatile trading.
AI Summary
BMY has effectively shifted from a Revlimidârecovery story to a cashâflowârich, portfolioâreplacement play where nearâterm valuation hinges on successful execution of a few pivotal readouts and disciplined capital allocationâmonitor upcoming ADEPTâ2/milvexian/iberdomide readouts and debt reduction progress closely, because adverse trial results or pricing shocks would meaningfully impair its highâleverage recovery.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |